{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:08:39Z","timestamp":1780376919017,"version":"3.54.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Acquired factor V deficiency (AFVD) is a rare disease characterized by a relative deficiency of coagulation factor V (FV) due to the presence of internal FV inhibitors. Patients may exhibit a range of symptoms from asymptomatic to severe bleeding. The heterogeneity of AFVD among clinical conditions makes its diagnosis challenging. Infection is a common secondary cause of FV inhibitors. This article reported a case of a patient with ulcerative colitis (UC) in the latent tuberculosis infection (LTBI) stage, who had abnormal initial screening of coagulation function. Traditional treatment strategies targeting the primary disease and empirical anti-infection therapy did not improve the patient's condition. It was not until the laboratory reported high-titer FV inhibitors followed by the clinical team providing immunomodulatory treatment with intravenous immunoglobulin and preventive anti-tuberculosis therapy, which successfully led to the elimination of FV inhibitors and significant improvement in the bleeding and infection symptoms of the primary disease. This article reviews relevant literature to provide ideas for the clinical diagnosis and treatment of rare factor inhibitors. To our knowledge, this is the first report of FV inhibitor in patients with UC during LTBI, as well as the first observation of a benefit in using immunoglobulin regimen to clear cycle inhibitors.<\/jats:p>","DOI":"10.3389\/fmed.2026.1755053","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:29:07Z","timestamp":1780374547000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Rare factor V inhibitor found in a patient with ulcerative colitis during latent tuberculosis infection"],"prefix":"10.3389","volume":"13","author":[{"given":"Yaodong","family":"Wang","sequence":"first","affiliation":[{"name":"Laboratory Medicine Center, The Second Hospital of Lanzhou University, The Second School of Clinical Medicine of Lanzhou University, Lanzhou University, Lanzhou","place":["Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Hospital of Lanzhou University, The Second School of Clinical Medicine of Lanzhou University, Lanzhou University, Lanzhou","place":["Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory Medicine Center, The Second Hospital of Lanzhou University, The Second School of Clinical Medicine of Lanzhou University, Lanzhou University, Lanzhou","place":["Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinchun","family":"He","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Hospital of Lanzhou University, The First School of Clinical Medicine of Lanzhou University, Lanzhou University, Lanzhou","place":["Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.37201\/req\/s03.20.2022","article-title":"Latent tuberculosis infection: approach and therapeutic schemes","volume":"35","author":"Fort\u00fan","year":"2022","journal-title":"Rev Espanola Quimioter Publ Offic Soc Espanola Quimioter."},{"key":"B2","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1139\/cjpp-2021-0008","article-title":"Quercetin modulates NRF2 and NF-\u03baB\/TLR-4 pathways to protect against isoniazid- and rifampicin-induced hepatotoxicity in vivo","volume":"99","author":"Sanjay","year":"2021","journal-title":"Can J Physiol Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"003380","DOI":"10.12890\/2022_003380","article-title":"Deranged haemostasis: rifampin-induced coagulopathy","volume":"9","author":"Tiperneni","year":"2022","journal-title":"Euro J Case Rep Int Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/ajh.10420","article-title":"High-dose intravenous immunoglobulin treatment in two patients with acquired factor V inhibitors","volume":"74","author":"de Raucourt","year":"2003","journal-title":"Am J Hematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11239-010-0529-6","article-title":"Acquired factor V inhibitors: a systematic review","volume":"31","author":"Franchini","year":"2011","journal-title":"J Thromb Thrombolysis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/00043426-199705000-00009","article-title":"Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin","volume":"19","author":"Tarantino","year":"1997","journal-title":"J Pediatr Hematol Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1055\/s-0042-1756196","article-title":"Activated partial thromboplastin time and prothrombin time mixing studies: current state of the art","volume":"49","author":"Adcock","year":"2023","journal-title":"Semin Thromb Hemost."},{"key":"B8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/ajh.25669","article-title":"Coagulation mixing studies: utility, algorithmic strategies and limitations for lupus anticoagulant testing or follow up of abnormal coagulation tests","volume":"95","author":"Favaloro","year":"2020","journal-title":"Am J Hematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1001\/jama.2023.23814","article-title":"What is ulcerative colitis?","volume":"331","author":"Voelker","year":"2024","journal-title":"Jama"},{"key":"B10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.7861\/clinmed.2021-0080","article-title":"Ulcerative colitis: an update","volume":"21","author":"Segal","year":"2021","journal-title":"Clin Med (London, Engl)."},{"key":"B11","doi-asserted-by":"publisher","first-page":"108203","DOI":"10.1016\/j.ijid.2025.108203","article-title":"Application of whole-genome sequencing for distinguishing relapse from reinfection in tuberculosis patients from Lithuania","volume":"162","author":"Vasiliauskaite","year":"2025","journal-title":"Int J Infect Dis IJID: Offi Publ Int Soc Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1182\/blood.V91.11.4188","article-title":"Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations","volume":"91","author":"Ortel","year":"1998","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4034","DOI":"10.1073\/pnas.0908526107","article-title":"Structural basis for the cooperative interplay between the two causative gene products of combined factor V and factor VIII deficiency","volume":"107","author":"Nishio","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.5858\/arpa.2016-0445-RS","article-title":"Factor V Inhibitors: a diagnostic and therapeutic challenge","volume":"141","author":"Olson","year":"2017","journal-title":"Arch Pathol Lab Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative colitis in adults: a review","volume":"330","author":"Gros","year":"2023","journal-title":"Jama"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3390\/biology13121083","article-title":"Autoimmune diseases and molecular mimicry in tuberculosis","volume":"13","author":"Churilov","year":"2024","journal-title":"Biology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2172-13-13","article-title":"Potential T cell epitopes of Mycobacterium tuberculosis that can instigate molecular mimicry against host: implications in autoimmune pathogenesis","volume":"13","author":"Chodisetti","year":"2012","journal-title":"BMC Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"13609","DOI":"10.3390\/ijms241713609","article-title":"Antibody cross-reactivity in auto-immune siseases","volume":"24","author":"Trier","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s12098-023-04928-8","article-title":"The intricate dance of infections and autoimmunity: an interesting paradox","volume":"91","author":"Rao","year":"2024","journal-title":"Indian J Pediatr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"102962","DOI":"10.1016\/j.jaut.2022.102962","article-title":"Infectious diseases, autoantibodies, and autoimmunity","volume":"137","author":"Johnson","year":"2023","journal-title":"J Autoimmun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"20251196","DOI":"10.1515\/biol-2025-1196","article-title":"PSME2 exacerbates ulcerative colitis by disrupting intestinal barrier function and promoting autophagy-dependent inflammation","volume":"20","author":"Li","year":"2025","journal-title":"Open Life Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.autrev.2013.06.004","article-title":"Innate and adaptive immunity in inflammatory bowel disease","volume":"13","author":"Geremia","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/1348-0421.13019","article-title":"Differential activation of innate and adaptive lymphocytes during latent or active infection with Mycobacterium tuberculosis","volume":"66","author":"Ruiz-S\u00e1nchez","year":"2022","journal-title":"Microbiol Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.4161\/hv.28249","article-title":"Immunotherapy of tuberculosis with Mycobacterium leprae Hsp65 as a DNA vaccine triggers cross-reactive antibodies against mammalian Hsp60 but not pathological autoimmunity","volume":"10","author":"Doimo","year":"2014","journal-title":"Hum Vaccin Immunother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/toxsci\/kfw218","article-title":"From the cover: characterization of isoniazid-specific T-cell clones in patients with anti-tuberculosis drug-related liver and skin injury","volume":"155","author":"Usui","year":"2017","journal-title":"Toxicol Sci Offi J Soc Toxicol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/eji.201343811","article-title":"Activated CD4+ T cells enter the splenic T-cell zone and induce autoantibody-producing germinal centers through bystander activation","volume":"44","author":"Banczyk","year":"2014","journal-title":"Eur J Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.pathol.2019.07.006","article-title":"Coagulation studies: achieving the right mix in a large laboratory network","volume":"51","author":"Blennerhassett","year":"2019","journal-title":"Pathology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1001\/jama.2016.15749","article-title":"Mixing Study for Evaluation of Abnormal Coagulation Testing","volume":"316","author":"Choi","year":"2016","journal-title":"Jama"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review","volume":"92","author":"Cervera","year":"2018","journal-title":"J Autoimmun."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.thromres.2006.03.012","article-title":"Interpretation of normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulants","volume":"119","author":"Devreese","year":"2007","journal-title":"Thromb Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1055\/s-2000-9823","article-title":"Factor VIII inhibitors. Laboratory diagnosis of inhibitors","volume":"26","author":"Sahud","year":"2000","journal-title":"Semin Thromb Hemost"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1656029","article-title":"Anti-factor VIII inhibitors and lupus anticoagulants in haemophilia A patients","author":"Blanco","year":"1997","journal-title":"Thromb Haemost"},{"key":"B35","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/bjh.17308","article-title":"Acquired factor V inhibitor: a nation-wide study of 38 patients","volume":"192","author":"Goulenok","year":"2021","journal-title":"Br J Haematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/46594","article-title":"Crystal structures of the membrane-binding C2 domain of human coagulation factor V","volume":"402","author":"Macedo-Ribeiro","year":"1999","journal-title":"Nature."},{"key":"B37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1161\/01.ATV.0000109750.34073.f6","article-title":"Modulation of factor V levels in plasma by polymorphisms in the C2 domain","volume":"24","author":"Scanavini","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000121826","article-title":"Assun\u00e7\u00e3o e Silva E, Santos FL, de Oliveira MH. The diversity in clinical presentation of acquired factor V inhibitor two case reports","volume":"119","author":"Gadelha","year":"2008","journal-title":"Acta Haematol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1046\/j.1537-2995.2002.00011.x","article-title":"Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure","volume":"42","author":"Streiff","year":"2002","journal-title":"Transfusion."},{"key":"B40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ajh.2830490122","article-title":"Coagulopathy due to an acquired factor V inhibitor and subsequently thrombosis","volume":"49","author":"George","year":"1995","journal-title":"Am J Hematol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/ajh.21056","article-title":"Successful treatment with rituximab in a patient with an acquired factor V inhibitor","volume":"83","author":"Lebrun","year":"2008","journal-title":"Am J Hematol."},{"key":"B42","author":"Taillan","year":"1990","journal-title":"Presse Medicale (Paris, France: 1983)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1097\/00042737-200212000-00016","article-title":"Acquired inhibitors to coagulation factors in patients with gastrointestinal diseases","volume":"14","author":"Kyriakou","year":"2002","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"264","DOI":"10.5603\/PiAP.2014.0031","article-title":"Pulmonary embolism in a young male with tuberculosis and factor V Leiden","volume":"82","author":"Skowro\u0144ski","year":"2014","journal-title":"Pneumonol Alergol Pol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"24337","DOI":"10.1136\/bcr-2021-243337","article-title":"Right ventricular thrombus and pulmonary embolism after infliximab therapy for ulcerative colitis","volume":"14","author":"Ogilvie","year":"2021","journal-title":"BMJ Case Reports"},{"key":"B46","first-page":"1483","article-title":"A circulating inhibitor specific to factor V. Clinical, biological and therapeutic study","volume":"10","author":"Lerolle","year":"1981","journal-title":"Nouv Presse Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1183\/09031936.93.03010109","article-title":"Acquired factor V deficiency in a patient with pulmonary tuberculosis","volume":"3","author":"Aliaga","year":"1990","journal-title":"Euro Respir J"},{"key":"B48","author":"Takase","year":"1980"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1755053\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:29:16Z","timestamp":1780374556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1755053\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":48,"alternative-id":["10.3389\/fmed.2026.1755053"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1755053","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"article-number":"1755053"}}